US FDA Charges Roy Ramancha: Counterfeit Ozempic Smuggling Scheme

• Federal charges have been filed against Indian nationals Swapnadip Roy, 33, and Vicky Ramancha, 37, for conspiracy and smuggling.
• The charges relate to an alleged transnational scheme to distribute counterfeit Ozempic, sourced from China, between July 2023 and April 2024.
• The counterfeit products included deceptive packaging, inserts, pen labels, and needles, sold at discounted prices to U.S. distributors.
• The U.S. Food and Drug Administration’s Office of Criminal Investigations assisted in the probe, which found alleged continued distribution even after FDA public warnings in December 2023.
• Acting FDA Commissioner Kyle Diamantas emphasized that counterfeit drugs pose a direct threat to public health and patient safety.

The infiltration of the American drug supply with fraudulent products represents a severe danger to public health and patient safety, extending beyond mere criminal activity.

Federal authorities have announced charges against two Indian nationals, Swapnadip Roy, 33, and Vicky Ramancha, 37, in connection with an alleged transnational counterfeit prescription drug distribution scheme. The U.S. Attorney’s Office for the Middle District of Florida, alongside the Criminal Division of the U.S. Department of Justice, brought conspiracy and smuggling charges against the individuals. This development highlights a significant effort by law enforcement to combat the illicit trade of pharmaceuticals, with the U.S. Food and Drug Administration’s Office of Criminal Investigations (US FDA Office of Criminal Investigations) providing crucial assistance in the probe.

The charges against Roy and Ramancha specifically allege their involvement in obtaining counterfeit Ozempic from unauthorized sources located in China. According to court documents, this operation spanned from July 2023 to April 2024. The counterfeit products were designed to deceive, featuring fake packaging, package inserts, pen labels, and even needles, all intended to mislead pharmacies and patients into believing they were receiving authentic, manufacturer-authorized medication. The alleged scheme involved selling these fraudulent products to other co-conspirators and distributors within the United States at significantly reduced prices, underscoring the profit motive behind such dangerous activities.

Crucially, the indictment further alleges that Roy, Ramancha, and their associates continued their distribution of counterfeit Ozempic even after the FDA issued public safety alerts and conducted a seizure in December 2023. These warnings were specifically aimed at informing consumers, pharmacies, and healthcare providers about the presence of counterfeit Ozempic products in the market. The persistence of the alleged Ozempic smuggling conspiracy despite regulatory intervention underscores the challenges faced by authorities in protecting the integrity of the pharmaceutical supply chain

The U.S. Food and Drug Administration (FDA) has been actively involved in addressing the threat posed by counterfeit medications. Acting FDA Commissioner of Food and Drugs, Kyle Diamantas, J.D., emphasized the gravity of the situation, stating that the infiltration of the American drug supply with fraudulent products represents a severe danger to public health and patient safety, extending beyond mere criminal activity. The agency has pledged to relentlessly pursue illicit networks, regardless of their complexity or international reach, to ensure accountability for those who seek to profit from counterfeit medicines.

This case, prosecuted in the Middle District of Florida, underscores the FDA’s commitment to safeguarding the nation's drug supply. The agency takes all reports of potential counterfeit or tampered medicines seriously, collaborating closely with other federal entities and the private sector to protect consumers. The FDA encourages the public, including online sellers, to report any suspected counterfeit products through its official channels, reinforcing a collective effort to maintain drug safety and efficacy.

The alleged transnational counterfeit drug scheme involving Roy and Ramancha highlights the persistent global challenge of securing pharmaceutical supply chains against fraudulent products. The FDA, as an agency within the U.S. Department of Health and Human Services, bears a broad mandate to protect public health, encompassing the safety, effectiveness, and security of human and veterinary drugs, vaccines, biological products, and medical devices. Its responsibilities also extend to the safety of the nation’s food supply, cosmetics, dietary supplements, radiation-emitting electronic products, and tobacco regulation.

This investigation and the resulting FDA charges against Roy Ramancha counterfeit Ozempic serve as a stark reminder of the potential for dangerous, unapproved substances to enter legitimate distribution channels. The alleged use of deceptive packaging and components in this case illustrates the sophisticated methods employed by those involved in such illicit operations. While an indictment represents an allegation and all defendants are presumed innocent until proven guilty, the ongoing efforts by the FDA and its partners are critical in mitigating the risks posed by counterfeit drugs to patient well-being across the country.

This development signals heightened enforcement risk for entities within the pharmaceutical supply chain, particularly those involved in distribution or online sales. Lawyers and compliance officers should advise clients to reinforce due diligence processes to verify product authenticity and supplier legitimacy, and to promptly act on FDA warnings to avoid potential criminal charges related to counterfeit drug distribution.

Source: Reporting based on U.S. Attorney's Office and FDA announcements.